nach oben

Erschienen in:

01.06.2009 | Article

Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis

verfasst von: C. C. Lee, A. I. Adler, M. S. Sandhu, S. J. Sharp, N. G. Forouhi, S. Erqou, R. Luben, S. Bingham, K. T. Khaw, N. J. Wareham

Erschienen in: Diabetologia | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

We examined the association between serum C-reactive protein (CRP) and incident diabetes in a prospective study, and added these data to a literature-based meta-analysis to explore potential sources of heterogeneity between studies.

Methods

We analysed a case–control study nested within the European Prospective Investigation of Cancer (EPIC)-Norfolk cohort, including 293 incident diabetes cases and 708 controls. We combined 16 published studies on CRP and incident diabetes in a random-effect meta-analysis.

Results

In the EPIC-Norfolk cohort, serum CRP was associated with a higher risk of diabetes after adjusting for age, sex, BMI, family history of diabetes, smoking and physical activity (OR 1.49, comparing the extreme thirds of CRP distribution [95% CI 1.03–2.15], p = 0.03). However, the association was completely attenuated after further adjustment for WHR, serum γ-glutamyltransferase and serum adiponectin (OR 1.00; 95% CI 0.66–1.51, p = 1.0). In a meta-analysis of 16 published studies with 3,920 incident diabetes cases and 24,914 controls, the RR was 1.72 (95% CI 1.54–1.92), comparing the extreme thirds of CRP distribution, with substantial heterogeneity between studies (I ² = 52.8%, p = 0.007).

Conclusions/interpretation

Initial evidence of association between CRP and incident diabetes was confounded by central adiposity, markers of liver dysfunction and adiponectin in the primary analysis. Despite an overall positive association in the meta-analysis, considerable heterogeneity existed between studies. The degree of adjustment for central adiposity and baseline glycaemia explained some of this heterogeneity and suggests that CRP may not be an independent risk factor for type 2 diabetes.

Pickup JC, Crook MA (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241–1248PubMedCrossRef

Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511PubMedCrossRef

Dehghan A, Kardys I, de Matt MPM et al (2007) Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56:872–878PubMedCrossRef

Doi Y, Kiyohara Y, Kubo M et al (2005) Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population. Diabetes Care 28:2497–2500PubMedCrossRef

Laaksonen DE, Niskanen L, Nyyssonen K et al (2004) C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 47:1403–1410PubMedCrossRef

Hu FB, Meigs JB, Li TY, Rifai N, Manson JE (2004) Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53:693–700PubMedCrossRef

Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N (2003) Elevated C-reactive protein is risk factor for the development of type 2 diabetes in Japanese American. Diabetes Care 26:2754–2757PubMedCrossRef

Spranger J, Kroke A, Mohlig M et al (2003) Inflammatory cytokines and the risk to develop type 2 diabetes. Diabetes 52:812–817PubMedCrossRef

Freeman DJ, Norrie J, Caslake MJ et al (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596–1600PubMedCrossRef

10.

Barzilay JI, Abraham L, Heckbert SR et al (2001) The relation of markers of inflammation to the development of glucose disorders in the elderly. The Cardiovascular Health Study. Diabetes 50:2384–2389PubMedCrossRef

11.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334PubMedCrossRef

12.

Thorand B, Lowel H, Schneider A et al (2003) C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men. Arch Intern Med 163:93–99PubMedCrossRef

13.

Duncan BB, Schmidt MI, Pankow JS et al (2003) Low-grade systemic inflammation and the development of type 2 diabetes. The Atherosclerosis Risk in Communities Study. Diabetes 52:1799–1805PubMedCrossRef

14.

Festa A, D’Agostino R, Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes 51:1131–1137PubMedCrossRef

15.

Krakoff J, Funahashi T, Stehouwer CDA et al (2003) Inflammatory markers, adiponectin and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26:1745–1751PubMedCrossRef

16.

Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM (2002) Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25:2016–2021PubMedCrossRef

17.

Snijder M, Dekker JM, Visser M et al (2003) Prospective relation of C-reactive protein with type 2 diabetes. Diabetes Care 26:1656–1657PubMedCrossRef

18.

Thorand B, Baumert J, Kolb H et al (2007) Sex differences in the prediction of type 2 diabetes by inflammatory markers. Result from the MONICA/KORA Augsburg case–cohort study, 1984–2002. Diabetes Care 30:854–860PubMedCrossRef

19.

Lindsay RS, Funahashi T, Hanson RL et al (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–58PubMedCrossRef

20.

Spranger J, Kroke A, Mohlig M et al (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228PubMedCrossRef

21.

Duncan BB, Schmidt MI, Pankow JS et al (2004) Adiponectin and the development of type 2 diabetes. Diabetes 53:2473–2478PubMedCrossRef

22.

Lee DH, Silventoinen K, Jacobs DR Jr, Jousilahti P, Tuomileto J (2004) Gamma-glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 89:5410–5414PubMedCrossRef

23.

Nannipieri M, Gonzales C, Baldi S et al (2005) Liver enzymes, the metabolic syndrome and incident diabetes: the Mexico City Diabetes Study. Diabetes Care 28:1757–1762PubMedCrossRef

24.

Andre P, Balkau B, Born C, Charles MA, Eschwege E (2006) Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the DESIR cohort. Diabetologia 49:2599–2603PubMedCrossRef

25.

Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB (2004) Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 27:1680–1687PubMedCrossRef

26.

Lee DH, Jacobs DR Jr (2005) Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis 178:327–330PubMedCrossRef

27.

Day N, Oakes S, Luben R et al (1999) EPIC-Norfolk: study design, characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 80(Suppl 1):95–103PubMed

28.

Harding AH, Day NE, Khaw KT et al (2004) Dietary fat and the risk of clinical type 2 diabetes: the European Prospective of Cancer—Norfolk Study. Am J Epidemiol 159:73–82PubMedCrossRef

29.

Forouhi NG, Harding AH, Allison M et al (2007) Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 50:949–956PubMedCrossRef

30.

Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analysis of prospective studies. JAMA 279:1477–1482PubMedCrossRef

31.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analysis. BMJ 327:557–560PubMedCrossRef

32.

Yoneda M, Mawatari H, Fujita K et al (2007) High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 42:573–582PubMedCrossRef

33.

Rantala AO, Lilja M, Kauma H, Savolainen MJ, Reunanen A, Kesaniemi YA (2000) Gamma-glutamyl transpeptidase and the metabolic syndrome. J Intern Med 248:230–238PubMedCrossRef

34.

Kang YH, Min HK, Son SM, Kim IJ, Kim YK (2007) The association of serum gamma glutamyltransferase with components of the metabolic syndrome in the Korean adults. Diabetes Res Clin Pract 77:306–313PubMedCrossRef

35.

Sakugawa H, Nakayoshi T, Kobashigawa K et al (2004) Metabolic syndrome is directly associated with gamma glutamyl transpeptidase elevation in Japanese women. World J Gastroenterol 10:1052–1055PubMed

36.

Yuan G, Chen X, Ma Q et al (2007) C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J Endocrinol 194:275–281PubMedCrossRef

37.

Hamdy O, Porramatikul S, Al-Ozairi E (2006) Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev 2:367–373PubMed

38.

Greenfield JR, Samaras K, Jenkins AB et al (2004) Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation 109:3022–3028PubMedCrossRef

39.

Manning PJ, Sutherland WH, Allum AR, de Jong SA, Jones SD (2002) Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with type 2 diabetes. Diabet Med 19:847–852PubMedCrossRef

40.

Meier-Ewert HK, Ridker PM, Rifai N et al (2001) Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 47:426–430PubMed

41.

Danesh J, Wheeler JG, Hirschfield GM et al (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387–1397PubMedCrossRef

Titel: Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis
verfasst von: C. C. Lee
A. I. Adler
M. S. Sandhu
S. J. Sharp
N. G. Forouhi
S. Erqou
R. Luben
S. Bingham
K. T. Khaw
N. J. Wareham
Publikationsdatum: 01.06.2009
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 6/2009
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-009-1338-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis